Clinical Trial Search

Primary: Mean POS Plasma Concentrations on Days 2, 3, and 8. — 230; 346; 637 ng/mL

Primary: Pain Scores (Verbal Numerical Rating Scale;VNRS) During Postoperative Hours. — 7; 5; 6; 5 Units on a scale

Primary: The Participant's Assessment of Discomfort at the Infusion Site on a Visual Analog Scale (VAS) — 20.0; 9.4 mm

Primary: The Percentage of Participants Achieving ≥30% Decrease From Baseline in Pain Intensity as Measured by WOMAC (Western Ontario and McMaster Universities Osteoarthritis…

Primary: Physician's Global Assessment (PGA) of Change Over Time (Good or Better) — 7; 0; 2; 9 participants

Primary: Attention Deficit Hyperactivity Disorder Rating Scale (ADHD RS) — 12.8 Units on a Scale

Primary: Change From Baseline in Trunk-to-limb Fat Ratio as Measured by Dual Energy X-Ray Absortiometry (DEXA) at Week 48 — 0.02; -0.02; 0.02; -0.01 ratio — p=0.48

Primary: Visual Acuity — 0.54; 0.06; 0.03; 0.04 logMAR

Primary: Physician Global Assessment of Psoriasis (PGA) Score - Mean Value Over 54 Weeks — 1.98; 2.51 units on scale — p=<0.001

Primary: Number of Participants With Moderate and Severe Postreperfusion Syndrome (PRS) — 15; 25 participants

Primary: Change in the Urticaria Activity Score (UAS) From Baseline to the Final Week for Desloratadine 5 mg Versus Desloratadine 20 mg — -1.0; -1.0; -1.1; 2.9 Units on a scale…

Primary: Average Number of Catheterizations Without Leaking Per Day — 2.4; 1.5 Number of Dry Catheterizations per Day

Primary: Number of Participants With Measurable Plasma Concentrations, by Age Group — 36; 17; 10; 9 participants

Primary: Number of Patients Achieving Remission — 554; 207 participants

Primary: Hemoglobin A1c (HbA1c) at 16 Week Endpoint — 7.71; 7.84 percent HbA1c — p=0.2519